Sickle cell disease pathophysiology

ESH eLearning, Jacques Elion, 219038

Thalassaemias

ESH eLearning, Maria Domenica Cappellini, 219039

Malaria and red cell disorders

ESH eLearning, Michael Lanzer, 219040

Epidemiology of red cell disorders

ESH eLearning, Frédéric B. Piel, 219041

Red cell senescence and storage lesions

ESH eLearning, Giel Bosman, 219042

Erythroid niche and erythroblast maturation

ESH eLearning, Mohandas Narla, 219034

Epigenetics in erythropoiesis

ESH eLearning, Gordon D. Ginder, 219035

Heme synthesis and iron metabolism

ESH eLearning, Laurent Gouya, 219036

Red cells and oxidative stress

ESH eLearning, Lucia De Franceschi, 219037

Richter transformation in the elderly patient:molecular origin and new strategies for improved therapies

ESH eLearning, Davide Rossi, 212197

Targeting the DNA Damage Response in high-risk lymphoma: biology and insights for future, less toxic approaches of therapy

ESH eLearning, Reinhardt Christian, 212198

Double hit and other types of high-risk lymphoma:molecular features and optimal management in the elderly patient

ESH eLearning, Paul Hamlin, 212199

Biology of AML at older age

ESH eLearning, Terrence N. Wong, 212185

Therapeutic management of the so-called “fit” older patient with AML

ESH eLearning, Bob Löwenberg, 212186

Management of the unfit patient with AML

ESH eLearning, Gert Ossenkoppele, 212187

The older patient with ALL

ESH eLearning, Hervé Dombret, 212188

Alloegeneic stem cell transplantation at older age

ESH eLearning, Nicolaus Kröger, 212189

Clonal evolution of multiple myeloma

ESH eLearning, Nikhil Munshi, 212190

MGUS and MGUS transition to myeloma, what do we need to do?

ESH eLearning, Irene Ghobrial, 212191

Multiple myeloma in the elderly, a particular challenge in light of numerous novel agents.

ESH eLearning, Jesús F. San-Miguel, 212192

Clonal evolution in malignant lymphoma

ESH eLearning, Jude FITZGIBBON, 212193

Management of indolent lymphoma in the elderly patient

ESH eLearning, Loretta Nastoupil, 212194

Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies

ESH eLearning, Farrukh Awan, 212195

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma

ESH eLearning, Loretta Nastoupil, 212196

DNA damage, a driving force of aging

ESH eLearning, Björn Schumacher, 212174

Clonal hematopoiesis

ESH eLearning, Benjamin Ebert, 212175

Clonal hematopoiesis

ESH eLearning, George Vassiliou, 212176

Selection of TP53 mutant clones following chemotherapy

ESH eLearning, Terrence N. Wong, 212177

Aging stem cells and stress

ESH eLearning, Michael Milsom, 212178

Anemia at older age

ESH eLearning, Nancy Berliner, 212179

Microenvironment and MDS

ESH eLearning, Rebekka Schneider, 212180

Biology of MDS

ESH eLearning, Benjamin Ebert, 212181

Management of high grade MDS

ESH eLearning, Pierre Fenaux, 212182

Management of CMML and other MDS/MPN entities

ESH eLearning, Raphael Itzykson, 212183

Assessing the aging individual with hematologic disorders: How geriatric assessment can define the fitness of an older patient

ESH eLearning, Tanya Wildes, 212184

The pathology of marginal zone lymphomas

ESH eLearning, German Ott, 210034

Marginal zone lymphoma: biology and molecular genetics

ESH eLearning, Ming Qing Du, 210035

Marginal zone lymphoma. Prognostic models.

ESH eLearning, Carlos Montalban, 210036

Clinical aspects

ESH eLearning, Catherine Thieblemont, 210037

Treatment of splenic marginal zone lymphoma

ESH eLearning, Barbara Kiesewetter, 210038

Treatment of nodal marginal zone lymphoma

ESH eLearning, Catherine Thieblemont, 210039

Treatment of MALT lymphoma

ESH eLearning, Emanuele Zucca, 210040

Novel targeted therapies in CL - Ibrutinib

ESH eLearning, John Gribben, 210025

Idelalisib

ESH eLearning, Michael J. Keating, 210026

Venetoclax

ESH eLearning, Peter Hillmen, 210027

Follicular lymphoma; from genetics to pathogenesis

ESH eLearning, Riccardo Dalla-Favera, 210028

Clonal evolution of follicular lymphoma

ESH eLearning, Michael R. Green, 210029

Integrating molecular diagnostics for improved patient stratification in follicular lymphoma

ESH eLearning, Oliver Weigert, 210030

Advanced stage patient, first line

ESH eLearning, Christian Buske, 210031

Treatment of follicular lymphoma (FL): Salvage therapy

ESH eLearning, Vincent Ribrag, 210032

New agents

ESH eLearning, Gilles Salles, 210033

Micro RNA dysregulation to identify targets for therapy in hematopoietic malignancies

ESH eLearning, Carlo M. Croce, 210019

Genetic portrait of CLL

ESH eLearning, Cathy Wu, 210020

Predictive biomarkers in CLL

ESH eLearning, Davide Rossi, 210021

FCR

ESH eLearning, Michael J. Keating, 210022

BR

ESH eLearning, Olivier Tournilhac, 210023

Chlorambucil plus anti-CD20 MoAb

ESH eLearning, Valentin Goede, 210024

Myeloma Hub

ESH eLearning, ESH , 204612

iCMLf Prize talk

ESH eLearning, Jerry Radich, 205141

John Goldman Prize Talk

ESH eLearning, Tim Hughes, 205140

Janet Rowley Prize talk

ESH eLearning, Mhairi Copland, 205142

Targeting non-coding RNAs in leukemia

ESH eLearning, Ramiro Garzon, 204647

Exportin (XPO1) inhibitors for the treatment of AML

ESH eLearning, Ramiro Garzon, 204648

Novel targets for AML

ESH eLearning, Ramiro Garzon, 204649

The spliceosome mutations that can cause hematological malignancies

ESH eLearning, Omar Abdel-Wahab, 204650

Efficacy of first generation FLT3 inhibitors for AML

ESH eLearning, Miguel Sanz, 204651

The need for collaboration amongst hospitals: learning from RATIFY

ESH eLearning, Miguel Sanz, 204652

The importance of collaboration in AML research

ESH eLearning, Omar Abdel-Wahab, 204660

Neomorphic mutations driving hematological cancers

ESH eLearning, Omar Abdel-Wahab, 204661

Therapeutics targeting splicing in hematological malignancies

ESH eLearning, Omar Abdel-Wahab, 204662

What are the drivers of leukemia?

ESH eLearning, Omar Abdel-Wahab, 204663

The benefits of patient advocacy groups

ESH eLearning, Jane Churpek, 204664

Developing an understanding of disease progression in MDS and AML

ESH eLearning, Jane Churpek, 204665

Balancing hereditary research with patient care in leukemia

ESH eLearning, Jane Churpek, 204666

Combination therapies and improving overall survival in AML

ESH eLearning, Mark Levis, 204667

The challenges of using kinase inhibitors for AML treatment

ESH eLearning, Mark Levis, 204668

AML clinical trials: early stage vs. relapse/refractory patients

ESH eLearning, Marion Subklewe, 204676

T-cell engaging antibodies: what lessons have we learnt?

ESH eLearning, Marion Subklewe, 204677

Upcoming clinical trials for venetoclax chemotherapy combinations for AML

ESH eLearning, Marina Konopleva, 204678

Providing the relevant information to patients: a changing approach in Spain

ESH eLearning, Jorge Sierra, 204679

What are the alternative treatment options for relapsed or elderly AML patients?

ESH eLearning, Jorge Sierra, 204680

Cytokine release syndrome: a limiting factor for AML treatment

ESH eLearning, John DiPersio, 204681

Bispecific agents: the future of AML and MDS treatment?

ESH eLearning, John DiPersio, 204682

The problem of treating AML with CD123-targeting drugs

ESH eLearning, John DiPersio, 204683

The use of second generation FLT3 inhibitors for AML

ESH eLearning, Francesco Lo-Coco, 204692

The standardization of molecular diagnostics for myeloid diseases in Italy

ESH eLearning, Francesco Lo-Coco, 204693

New treatments for AML using inhibitors

ESH eLearning, Francesco Lo-Coco, 204694

The future of leukemia treatment in the elderly

ESH eLearning, John DiPersio, 204695

When to use bispecifics for AML

ESH eLearning, John DiPersio, 204696

Expanding trials using bispecifics

ESH eLearning, John DiPersio, 204697

The challenges facing elderly AML treatment

ESH eLearning, Lars Bullinger, 204698

Adapting AML treatment for elderly patients

ESH eLearning, Lars Bullinger, 204699

CAR T-cells and CRISPR: The future of AML treatment

ESH eLearning, Saar Gill, 204708

The development of novel treatment modalities: regulations and expectations

ESH eLearning, Saar Gill, 204709

Transferring lessons learnt from treating ALL to AML

ESH eLearning, Saar Gill, 204710

Price vs. performance: CAR T-cells

ESH eLearning, Saar Gill, 204711

The potential of differentiation therapies for AML

ESH eLearning, Stéphane de Botton, 204712

The next steps for the IDH2 inhibitor drug enasidenib

ESH eLearning, Stéphane de Botton, 204713

Working with smaller research companies

ESH eLearning, Stéphane de Botton, 204714

The future of AML and MDS diagnosis and treatment

ESH eLearning, Stéphane de Botton, 204715